SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-229101
Filing Date
2023-09-06
Accepted
2023-09-06 07:18:03
Documents
13
Period of Report
2023-08-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d437171d8k.htm   iXBRL 8-K 34210
  Complete submission text file 0001193125-23-229101.txt   194439

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA qncx-20230830.xsd EX-101.SCH 3879
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE qncx-20230830_def.xml EX-101.DEF 13695
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE qncx-20230830_lab.xml EX-101.LAB 22681
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE qncx-20230830_pre.xml EX-101.PRE 14663
7 EXTRACTED XBRL INSTANCE DOCUMENT d437171d8k_htm.xml XML 5155
Mailing Address 601 GATEWAY BOULEVARD, SUITE 1250 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 1250 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Filer) CIK: 0001662774 (see all company filings)

IRS No.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38890 | Film No.: 231237847
SIC: 2836 Biological Products, (No Diagnostic Substances)